164 related articles for article (PubMed ID: 35815661)
81. Expression of carcinoembryonic antigen in peripheral- or central-located small cell lung cancer: its clinical significance.
Bandoh S; Fujita J; Ueda Y; Fukunaga Y; Dohmoto K; Hojo S; Yang Y; Yamaji Y; Takahara J; Ishida T
Jpn J Clin Oncol; 2001 Jul; 31(7):305-10. PubMed ID: 11518742
[TBL] [Abstract][Full Text] [Related]
82. REST Inactivation and Coexpression of ASCL1 and POU3F4 Are Necessary for the Complete Transformation of RB1/TP53-Inactivated Lung Adenocarcinoma into Neuroendocrine Carcinoma.
Masawa M; Sato-Yazawa H; Kashiwagi K; Ishii J; Miyata-Hiramatsu C; Iwamoto M; Kohno K; Miyazawa T; Onozaki M; Noda S; Shimizu Y; Niho S; Yazawa T
Am J Pathol; 2022 Jun; 192(6):847-861. PubMed ID: 35367201
[TBL] [Abstract][Full Text] [Related]
83. The balance between the expressions of hASH1 and HES1 differs between large cell neuroendocrine carcinoma and small cell carcinoma of the lung.
Nasgashio R; Sato Y; Matsumoto T; Kageyama T; Hattori M; Iyoda A; Satoh Y; Ryuge S; Masuda N; Jiang SX; Saegusa M
Lung Cancer; 2011 Dec; 74(3):405-10. PubMed ID: 21601304
[TBL] [Abstract][Full Text] [Related]
84. Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors.
Folpe AL; Gown AM; Lamps LW; Garcia R; Dail DH; Zarbo RJ; Schmidt RA
Mod Pathol; 1999 Jan; 12(1):5-8. PubMed ID: 9950155
[TBL] [Abstract][Full Text] [Related]
85. MicroRNA expression distinguishes SCLC from NSCLC lung tumor cells and suggests a possible pathological relationship between SCLCs and NSCLCs.
Du L; Schageman JJ; Irnov ; Girard L; Hammond SM; Minna JD; Gazdar AF; Pertsemlidis A
J Exp Clin Cancer Res; 2010 Jun; 29(1):75. PubMed ID: 20624269
[TBL] [Abstract][Full Text] [Related]
86. Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.
Meder L; König K; Fassunke J; Ozretić L; Wolf J; Merkelbach-Bruse S; Heukamp LC; Buettner R
Exp Mol Pathol; 2015 Dec; 99(3):682-6. PubMed ID: 26546837
[TBL] [Abstract][Full Text] [Related]
87. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers.
Yokomizo A; Tindall DJ; Drabkin H; Gemmill R; Franklin W; Yang P; Sugio K; Smith DI; Liu W
Oncogene; 1998 Jul; 17(4):475-9. PubMed ID: 9696041
[TBL] [Abstract][Full Text] [Related]
88. Whole-Process Treatment of Combined Small Cell Lung Cancer Initially Diagnosed as "Lung Squamous Cell Carcinoma": A Case Report and Review of the Literature.
Dong Y; Li Q; Li D; Fang Y; Wang C
Front Immunol; 2022; 13():831698. PubMed ID: 35309345
[TBL] [Abstract][Full Text] [Related]
89. [Prognostic and Predictive Value of Thyroid Transcription Factor-1, CD56, P40 and Other Clinical Characteristics in Small Cell Lung Cancer Patients].
Wang X; Zhang Y; Hu M; Wang R; Liu L; Qian K; Li Y; Zhi X
Zhongguo Fei Ai Za Zhi; 2017 Aug; 20(8):522-527. PubMed ID: 28855032
[TBL] [Abstract][Full Text] [Related]
90. Bronchoscopic Brushing from Central Lung Cancer-Next Generation Sequencing Results are Reliable.
Hagmeyer L; Fassunke J; Engels M; Treml M; Herkenrath S; Matthes S; Büttner R; Randerath W
Lung; 2019 Jun; 197(3):333-337. PubMed ID: 30824994
[TBL] [Abstract][Full Text] [Related]
91. P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens.
Švajdler M; Mezencev R; Ondič O; Šašková B; Mukenšnábl P; Michal M
Ann Diagn Pathol; 2018 Apr; 33():23-29. PubMed ID: 29566943
[TBL] [Abstract][Full Text] [Related]
92. Loss of expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification.
Shivapurkar N; Reddy J; Matta H; Sathyanarayana UG; Huang CX; Toyooka S; Minna JD; Chaudhary PM; Gazdar AF
Oncogene; 2002 Dec; 21(55):8510-4. PubMed ID: 12466971
[TBL] [Abstract][Full Text] [Related]
93. The small GTPase RhoA has greater expression in small cell lung carcinoma than in non-small cell lung carcinoma and contributes to their unique morphologies.
Varker KA; Phelps SH; King MM; Williams CL
Int J Oncol; 2003 Mar; 22(3):671-81. PubMed ID: 12579323
[TBL] [Abstract][Full Text] [Related]
94. Dynamic transition of molecular subtypes in relapsed small cell lung cancer treated with multimodal therapy: A case report.
Yasuda K; Haruki T; Miyamoto T; Oshima Y; Matsui S; Kubouchi Y; Nakamura H
Thorac Cancer; 2023 Jul; 14(20):2001-2004. PubMed ID: 37253435
[TBL] [Abstract][Full Text] [Related]
95. Small cell lung cancer - news in the tumour´s biology.
Pavlíčková K; Matěj R
Cesk Patol; 2023; 59(1):18-22. PubMed ID: 37072275
[TBL] [Abstract][Full Text] [Related]
96. Distinct regulation of ASCL1 by the cell cycle and chemotherapy in small cell lung cancer.
Liu Y; Wu Q; Jiang B; Hou T; Wu C; Wu M; Song H
Mol Cancer Res; 2024 Mar; ():. PubMed ID: 38512021
[TBL] [Abstract][Full Text] [Related]
97. Lung Cancer through Transcription Factors.
Papavassiliou KA; Anagnostopoulos N; Papavassiliou AG
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298412
[TBL] [Abstract][Full Text] [Related]
98. Identifying a missing lineage driver in a subset of lung neuroendocrine tumors.
Pozo K; Minna JD; Johnson JE
Genes Dev; 2018 Jul; 32(13-14):865-867. PubMed ID: 29967289
[TBL] [Abstract][Full Text] [Related]
99. Combined small cell lung cancer: current progress and unmet needs.
Zeng C; Qiu G; Xie X; Liu T; Chen Z; Zhang X; Zhou W; Lin X; Xie Z; Qin Y; Wang Y; Ma X; Zhou C; Liu M
Am J Cancer Res; 2023; 13(9):3864-3874. PubMed ID: 37818075
[TBL] [Abstract][Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
